Studying Tumor Tissue Samples and Blood Samples to Learn More About DNA Changes in Patients With Lung Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00899405|
Recruitment Status : Recruiting
First Posted : May 12, 2009
Last Update Posted : January 15, 2019
RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This laboratory study is looking at tumor tissue samples and blood samples to learn more about DNA changes in patients with lung cancer.
|Condition or disease|
- Examine the mutational status of the EGFR pathway in tumor and blood samples from patients with lung cancer.
- Correlate the EGFR pathway mutations in these samples with clinical outcomes of these patients.
OUTLINE: Archived tumor tissue and blood samples are analyzed via PCR to detect EGFR pathway mutations in DNA.
|Study Type :||Observational|
|Estimated Enrollment :||800 participants|
|Official Title:||EGFR Pathway Mutations in Lung Cancer Patient Tumors and Blood|
|Study Start Date :||May 2005|
|Estimated Primary Completion Date :||December 2019|
|Estimated Study Completion Date :||December 2019|
Patients with lung cancer
Collection of archival tumor specimen at the beginning of the study and collection of blood samples at the beginning of the study and then at regular intervals
- Mutational status of the EGFR pathway [ Time Frame: up to 1 year ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00899405
|United States, California|
|University of California Davis Cancer Center||Recruiting|
|Sacramento, California, United States, 95817|
|Contact: Clinical Trials Office - University of California Davis Cancer 916-734-3089|
|Principal Investigator:||Philip C. Mack, PhD||University of California, Davis|